ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
레브코비 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 희귀 질환에 대한 인식 향상, 유전성 질환 발생률 증가, 가정용 의료 솔루션 수요 증가, 건강 격차 해소 노력 강화, 전문 약국 시장 성장 등에 기인할 것으로 분석됩니다. 예측 기간의 주요 동향으로는 규제 지원 및 인센티브, 디지털 건강 기술의 통합, 유전자 치료의 발전, 제형 기술의 혁신, 의료 분야의 디지털 전환 등이 있습니다.
아데노신 데아미나제 중증 복합 면역 결핍증(ADA-SCID)의 발병률이 증가함에 따라 레브코비 시장의 성장이 촉진될 것으로 예상됩니다. ADA-SCID는 아데노신 데아미나제 효소가 심각하게 결핍되어 면역 기능이 저하되고 감염에 대한 취약성이 높아지는 희귀 유전 질환입니다. ADA-SCID 사례의 증가 이유는 희귀 유전성 면역 결핍 질환에 대한 진단 개선과 인식 제고 때문입니다. 레브코비는 아데노신 데아미나제(ADA)의 재조합 형태를 공급하는 효소 대체 요법으로, 아데노신과 데옥시아데노신의 독성 수준을 감소시켜 대사 균형을 회복하고 ADA-SCID 환자의 면역 기능을 개선합니다. 예를 들어, 미국 저널 웹사이트인 MedlinePlus에 따르면, 2024년 5월 현재 전 세계적으로 약 50만 명 중 1명의 신생아가 ADA 결핍증에 걸릴 것으로 추정되며, SCID 사례의 15%는 이 결핍증으로 인해 발생합니다. ADA-SCID 사례의 증가는 레브코비 시장의 성장에 기여하고 있습니다.
맞춤형 의약품의 확장은 레브코비 시장의 성장을 촉진할 것으로 예상됩니다. 맞춤형 의약품은 개인의 특정 유전적 및 분자적 프로필에 맞게 의료 치료를 맞춤화하는 진화하는 접근 방식입니다. 이 접근 방식은 예방, 진단 및 치료에서 환자별 요인을 고려하여 치료 효능을 개선하는 것을 목표로 합니다. 맞춤형 의약품의 성장은 유전 및 유전체 기술의 발전, 맞춤형 의료 서비스에 대한 환자의 수요 증가, 맞춤형 치료가 건강 결과 및 의료 효율성을 향상시킬 수 있다는 인식에 의해 촉진되고 있습니다. 레브코비는 희귀 유전 질환에 대한 전문적인 치료를 제공함으로써 맞춤형 의약품에 부합하며, 환자의 치료 결과를 개선하는 맞춤형 의료 전략의 광범위한 동향의 혜택을 받고 있습니다. Personalized Medicine Coalition에 따르면, 2022년에는 12개의 새로운 맞춤형 의약품이 승인되어 전체 신약의 34%를 차지하며, 이는 전년에 비해 상당한 증가를 보였습니다. 따라서 맞춤형 의약품의 성장은 레브코비 시장의 확장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 레브코비 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 레브코비 시장 : 성장률 분석
세계의 레브코비 시장 실적 : 규모와 성장(2019-2024년)
세계의 레브코비 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 레브코비 : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 레브코비 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
프리필드
바이알
세계의 레브코비 시장 : 질환별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
중증 복합 면역 결핍증(SCID)
아데노신 데아미나제 중증 복합 면역 결핍증(ADA-SCID)
세계의 레브코비 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
약국
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 레브코비 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 레브코비 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
레브 코비 시장 : 경쟁 구도
레브코비 시장 : 기업 프로파일
Leadiant Biosciences Inc.
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
레브코비 시장(2029년) : 새로운 기회를 제공하는 국가
레브코비 시장(2029년) : 새로운 기회를 제공하는 부문
레브코비 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Revcovi, also known as elapegademase-lvlr, is a recombinant enzyme therapy designed to treat adenosine deaminase severe combined immune deficiency (ADA-SCID), a rare genetic disorder that severely impairs the immune system. This therapy acts as a vital replacement for the missing adenosine deaminase enzyme, helping to reduce toxic metabolites and restore immune function in affected individuals.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary forms of revcovi include pre-filled syringes and vials. Pre-filled syringes contain a precise dose of medication, eliminating the need for manual preparation. They offer increased convenience, reduce contamination risks, and ensure dosing accuracy, particularly in both clinical and home care settings. The use of pre-filled syringes for Revcovi is expanding, as healthcare providers increasingly prefer them for their ease of use and accuracy in enzyme replacement therapies. Revcovi is indicated for conditions like severe combined immunodeficiency (SCID) and adenosine deaminase (ADA)-deficient SCID, with end users including hospitals and pharmacies.
The revcovi market research report is one of a series of new reports from The Business Research Company that provides revcovi market statistics, including the revcovi industry's global market size, regional shares, competitors with a revcovi market share, detailed revcovi market segments, market trends and opportunities, and any further data you may need to thrive in the revcovi industry. This revcovi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The revcovi market size is expected to see rapid growth in the next few years. It will grow to $66.9 million in 2029 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to growing awareness of rare diseases, rising incidence of genetic disorders, rising demand for home healthcare solutions, increasing focus on health equity, and growth of specialty pharmacies. Major trends in the forecast period include regulatory support and incentives, integration of digital health technologies, advancements in gene therapy, innovations in formulation technologies, and digital transformation in healthcare.
The increasing incidence of adenosine deaminase severe combined immunodeficiency (ADA-SCID) is expected to drive the growth of the revcovi market. ADA-SCID is a rare genetic disorder characterized by a severe deficiency of the adenosine deaminase enzyme, leading to compromised immune function and heightened vulnerability to infections. The rise in ADA-SCID cases is attributed to improved diagnosis and heightened awareness of rare genetic immunodeficiencies. Revcovi, an enzyme replacement therapy, delivers a recombinant form of adenosine deaminase (ADA), helping restore metabolic balance by reducing toxic levels of adenosine and deoxyadenosine, thus improving immune function in ADA-SCID patients. For example, according to MedlinePlus, a US-based journal website, in May 2024, ADA deficiency is estimated to affect approximately 1 in 500,000 newborns globally, with 15% of SCID cases resulting from this deficiency. This increase in ADA-SCID cases is contributing to the growth of the revcovi market.
The expansion of personalized medicine is expected to fuel the growth of the revcovi market. Personalized medicine is an evolving approach that tailors medical treatment to an individual's specific genetic and molecular profile. This approach aims to improve treatment efficacy by considering patient-specific factors in prevention, diagnosis, and therapy. The growth of personalized medicine is driven by advancements in genetic and genomic technologies, increased patient demand for customized healthcare, and the recognition that personalized treatments can enhance health outcomes and healthcare efficiency. Revcovi aligns with personalized medicine by offering specialized therapy for rare genetic disorders, benefiting from the broader trend toward personalized healthcare strategies that enhance patient outcomes. According to the Personalized Medicine Coalition, in 2022, 12 new personalized medications were approved, representing 34% of all new treatments, marking a significant rise compared to previous years. Thus, the growth of personalized medicine is contributing to the expansion of the revcovi market.
Rising healthcare expenditure is anticipated to support the growth of the revcovi market. Healthcare expenditure encompasses the total spending on healthcare services and products, including personal health care, preventive services, and public health initiatives, aimed at improving overall health outcomes. The increase in healthcare spending is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, rising drug costs, and inefficient payment models, alongside increased demand for healthcare services. This boost in healthcare expenditure benefits the Revcovi market by increasing funding for research, development, and the distribution of innovative treatments. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported that healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is contributing to the growth of the revcovi market.
The Key player operating in the revcovi market is Leadiant Biosciences Inc.
North America was the largest region in the revcovi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in revcovi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the revcovi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The revcovi market consists of sales of elapegademase-lvlr injection, pegylation, and enzyme replacement therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Revcovi Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on revcovi market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for revcovi ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The revcovi market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Pre-Filled; Vial
2) By Clinical Indication: Severe Combined Immunodeficiency (SCID); Adenosine Deaminase (ADA)-Deficient SCID
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Revcovi Market Characteristics
3. Revcovi Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Revcovi Market Trends And Strategies
5. Revcovi Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Revcovi Growth Analysis And Strategic Analysis Framework
6.1. Global Revcovi PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Revcovi Market Growth Rate Analysis
6.4. Global Revcovi Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Revcovi Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Revcovi Total Addressable Market (TAM)
7. Global Revcovi Market Pricing Analysis & Forecasts
8. Revcovi Market Segmentation
8.1. Global Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pre-Filled
Vial
8.2. Global Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Combined Immunodeficiency (SCID)
Adenosine Deaminase (ADA)-Deficient SCID
8.3. Global Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Pharmacy
9. Global Revcovi Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Revcovi Market Regional And Country Analysis
10.1. Global Revcovi Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Revcovi Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Asia-Pacific Revcovi Market
11.1. Asia-Pacific Revcovi Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. China Revcovi Market
12.1. China Revcovi Market Overview
12.2. China Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
13. India Revcovi Market
13.1. India Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. Japan Revcovi Market
14.1. Japan Revcovi Market Overview
14.2. Japan Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Australia Revcovi Market
15.1. Australia Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. South Korea Revcovi Market
16.1. South Korea Revcovi Market Overview
16.2. South Korea Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Western Europe Revcovi Market
17.1. Western Europe Revcovi Market Overview
17.2. Western Europe Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. UK Revcovi Market
18.1. UK Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Germany Revcovi Market
19.1. Germany Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. France Revcovi Market
20.1. France Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Revcovi Market
21.1. Eastern Europe Revcovi Market Overview
21.2. Eastern Europe Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. North America Revcovi Market
22.1. North America Revcovi Market Overview
22.2. North America Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. USA Revcovi Market
23.1. USA Revcovi Market Overview
23.2. USA Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. Canada Revcovi Market
24.1. Canada Revcovi Market Overview
24.2. Canada Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. South America Revcovi Market
25.1. South America Revcovi Market Overview
25.2. South America Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. Middle East Revcovi Market
26.1. Middle East Revcovi Market Overview
26.2. Middle East Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Africa Revcovi Market
27.1. Africa Revcovi Market Overview
27.2. Africa Revcovi Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Revcovi Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Revcovi Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Revcovi Market Competitive Landscape And Company Profiles
28.1. Revcovi Market Competitive Landscape
28.2. Revcovi Market Company Profiles
28.2.1. Leadiant Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
29. Global Revcovi Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Revcovi Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Revcovi Market
32. Recent Developments In The Revcovi Market
33. Revcovi Market High Potential Countries, Segments and Strategies
33.1 Revcovi Market In 2029 - Countries Offering Most New Opportunities
33.2 Revcovi Market In 2029 - Segments Offering Most New Opportunities
33.3 Revcovi Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. The Business Research Company
34.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
